The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Pharmacodynamics and pharmacokinetics of nonsteroidal anti‐inflammatory drugs in species of veterinary interest
Open accessAbstract
This review summarises selected aspects of the pharmacokinetics (PK) and pharmacodynamics (PD) of nonsteroidal anti‐inflammatory drugs (NSAIDs). It is not intended to be comprehensive, in that it covers neither minor species nor several important aspects of NSAID PD. The limited objective of the review is to summarise those aspects of NSAID PK and PD, which are important to an understanding of PK–PD integration and PK–PD modelling (the subject of the next review in this issue). The general features of NSAID PK are: usually good bioavailability from oral, intramuscular and subcutaneous administration routes (but with delayed absorption in horses and ruminants after oral dosing), a high degree of binding to plasma protein, low volumes of distribution, limited excretion of administered dose as parent drug in urine, marked inter‐species differences in clearance and elimination half‐life and ready penetration into and slow clearance from acute inflammatory exudate. The therapeutic effects of NSAIDs are exerted both locally (at peripheral inflammatory sites) and centrally. There is widespread acceptance that the principal mechanism of action (both PD and toxicodynamics) of NSAIDs at the molecular level comprises inhibition of cyclooxygenase (COX), an enzyme in the arachidonic acid cascade, which generates inflammatory mediators of the prostaglandin group. However, NSAIDs possess also many other actions at the molecular level. Two isoforms of COX have been identified. Inhibition of COX‐1 is likely to account for most of the side‐effects of NSAIDs (gastrointestinal irritation, renotoxicity and inhibition of blood clotting) but a minor contribution also to some of the therapeutic effects (analgesic and anti‐inflammatory actions) cannot be excluded. Inhibition of COX‐2 accounts for most and possibly all of the therapeutic effects of NSAIDs. Consequently, there has been an intensive search to identify and develop drugs with selectivity for inhibition of COX‐2. Whole blood in vitro assays are used to investigate quantitatively the three key PD parameters (efficacy, potency and sensitivity) for NSAID inhibition of COX isoforms, providing data on COX‐1:COX‐2 inhibition ratios. Limited published data point to species differences in NSAID‐induced COX inhibition, for both potency and potency ratios. Members of the 2‐arylpropionate sub‐groups of NSAIDs exist in two enantiomeric forms [R‐(−) and S‐(+)] and are licensed as racemic mixtures. For these drugs there are marked enantiomeric differences in PK and PD properties of individual drugs in a given species, as well as important species differences in both PK and PD properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., & Herschman, H. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98774-0 · Cited by 1,789
Aspirin Selectively Inhibits Prostaglandin Production in Human Platelets
SMITH, J. B., & WILLIS, A. L. (1971) · Nature New Biology · doi:10.1038/newbio231235a0 · Cited by 1,521
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Inducible cyclooxygenase may have anti-inflammatory properties
Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., & Willoughby, D. A. (1999) · Nature Medicine · doi:10.1038/9550 · Cited by 1,242
The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes.
Fu, J. Y., Masferrer, J. L., Seibert, K., Raz, A., & Needleman, P. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44821-6 · Cited by 944
Pharmacological analysis of cyclooxygenase-1 in inflammation
Smith, C. J., Zhang, Y., Koboldt, C. M., Muhammad, J., Zweifel, B. S., Shaffer, A., Talley, J. J., Masferrer, J. L., Seibert, K., & Isakson, P. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13313 · Cited by 807
Malmberg, A. B., & Yaksh, T. L. (1992) · Science · doi:10.1126/science.1381521 · Cited by 710
Malmberg, A. B., & Yaksh, T. L. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10314-5 · Cited by 643
Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology
Ari�ns, E. J. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541922 · Cited by 609
Hutt, A. J., & Caldwell, J. (1983) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1983.tb02874.x · Cited by 394
Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
Cowan, K. N., Heilbut, A., Humpl, T., Lam, C., Ito, S., & Rabinovitch, M. (2000) · Nature Medicine · doi:10.1038/76282 · Cited by 378
Mechanism of Action of Acetaminophen: Is There a Cyclooxygenase 3?
Botting, R. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317520 · Cited by 350
Wallace, J. L., Bak, A., McKnight, W., Asfaha, S., Sharkey, K. A., & MacNaughton, W. K. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70370-1 · Cited by 336
Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?
Warner, T. D., & Mitchell, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222543099 · Cited by 302
COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease
Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R. (2000) · The Lancet · doi:10.1016/s0140-6736(99)12031-2 · Cited by 298
In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats
Brideau, C., Van Staden, C., & Chan, C. C. (2001) · American Journal of Veterinary Research · doi:10.2460/ajvr.2001.62.1755 · Cited by 210
Evans, A. M. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00266343 · Cited by 207
McCann, M. E., Andersen, D. R., Zhang, D., Brideau, C., Black, W. C., Hanson, P. D., & Hickey, G. J. (2004) · American Journal of Veterinary Research · doi:10.2460/ajvr.2004.65.503 · Cited by 132
COX-3: just another COX or the solitary elusive target of paracetamol?
Schwab, J. M., Schluesener, H. J., & Laufer, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12841-3 · Cited by 125
Wallace, J. L., Chapman, K., & McKnight, W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702420 · Cited by 124
Evidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib
Paulson, S. K., Engel, L., Reitz, B. A., Bolten, S., Burton, E. G., Maziasz, T. J., Yan, B., & Schoenhard, G. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15037-4 · Cited by 119
Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood
Streppa, H. K., Jones, C. J., & Budsberg, S. C. (2002) · American Journal of Veterinary Research · doi:10.2460/ajvr.2002.63.91 · Cited by 102
Young, J. M., Panah, S., Satchawatcharaphong, C., & Cheung, P. S. (1996) · Inflammation Research · doi:10.1007/bf02259611 · Cited by 97
Francischi, J. N., Chaves, C. C., Moura, A., Lima, A. S., Rocha, O. A., Ferreira-Alves, D. L., & Bakhle, Y. S. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704937 · Cited by 91
Wilson, J. E., Chandrasekharan, N. V., Westover, K. D., Eager, K. B., & Simmons, D. L. (2004) · American Journal of Veterinary Research · doi:10.2460/ajvr.2004.65.810 · Cited by 88
Pairet, M., & van Ryn, J. (1998) · Inflammation Research · doi:10.1007/s000110050289 · Cited by 87
Selective COX-2 inhibitors: is the water becoming muddy?
Wallace, J. L. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01283-8 · Cited by 82
Principles of pharmacodynamics and their applications in veterinary pharmacology
Lees, P., Cunningham, F. M., & Elliott, J. (2004) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2004.00620.x · Cited by 80
Self-citationStereoselectivity in clinical pharmacokinetics and drug development
Campbell, D. B. (1990) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190194 · Cited by 71
Dolan, S., & Nolan, A. M. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00200-2 · Cited by 64
Villanueva, M., Heckenberger, R., Strobach, H., Palmer, M., & Schrör, K. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb05690.x · Cited by 64
Cyclooxygenase‐2 inhibitors: promise or peril?
Mengle-Gaw, L. J., & Schwartz, B. D. (2002) · Mediators of Inflammation · doi:10.1080/09629350290000041 · Cited by 52
Pharmacokinetic profile andin vitroselective cyclooxygenase‐2 inhibition by nimesulide in the dog
Toutain, P., Cester, C. C., Haak, T., & Metge, S. (2001) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1046/j.1365-2885.2001.00303.x · Cited by 52
Self-citationFajt, V. R., Apley, M. D., Roth, J. A., Frank, D. Ε., Brogden, K. A., Skogerboe, T. L., Shostrom, V., & Chin, Y.-L. (2003) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1046/j.1365-2885.2003.00477.x · Cited by 51
Dolan, S., Kelly, J. G., Huan, M., & Nolan, A. (2003) · Anesthesiology · doi:10.1097/00000542-200301000-00027 · Cited by 35
Cheng, Z., Nolan, A. M., & McKellar, Q. (2002) · American Journal of Veterinary Research · doi:10.2460/ajvr.2002.63.782 · Cited by 17
Cited by
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Pharmacologically active compounds in the environment and their chirality
Kasprzyk-Hordern, B. (2010) · Chemical Society Reviews · doi:10.1039/c000408c · Cited by 456
Health concerns and management of select veterinary drug residues
Baynes, R. E., Dedonder, K., Kissell, L., Mzyk, D., Marmulak, T., Smith, G., Tell, L., Gehring, R., Davis, J., & Riviere, J. E. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2015.12.020 · Cited by 338
Chibisa, G. E., Vinyard, J. R., & Laarman, A. H. (2018) · Journal of Dairy Science · doi:10.3168/jds.2018-14493 · Cited by 13
Metadata
- Authors
- LEES, P., LANDONI, M. F., Giraudel, J., & TOUTAIN, P. L.
- Venue
- Journal of Veterinary Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 27
- Issue
- 6
- Pages
- 479-490
- ISSN
- 0140-7783 (ISSN-L)
- 1365-2885
- OpenAlex
- W2009228494
- Cited by
- 310
- References
- 38
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.